Home
Research
Basilea
Diurnal Group
About
Services
Contact
Partners
Sign up
Blog
More
Use tab to navigate through the menu items.
Basilea Pharmaceutica
7 June 2022
Anti-infectives prospects
Important period ahead
10 March 2022
Strategic change
Refocusing on anti-infectives
19 November 2021
Update on derazantinib
Can derazantinib be class leading?
1 September 2021
Post H1 Results update
Firing on all fronts
6 July 2021
Lisavanbulin revisited
Showing lots of promise
31 May 2021
Update on derazantinib clinical programs
Establishing optimum positioning
19 May 2021
CARB-X award
Novel antibiotic development expertise apparent
6 May 2021
Ceftobiprole
Bacteraemia is the key
24 March 2021
FIDES-01 Interim results
Derazantinib differentiation apparent
22 February 2021
Lisavanbulin
Lisavanbulin in Focus
16 February 2021
Full Year 2020
Solid results and more to come
21 December 2020
Derazantinib
The overlooked FGFR inhibitor
19 October 2020
Initiation of coverage
The best is yet to come
Please subscribe to receive our research, articles and invitations as soon as they are available. Our research is classified as a ‘minor non-monetary benefit’ as defined by
the Markets in Financial Instruments Directive II
.
Subscribe
Thank you for subscribing